Network Insights Methodology Get Access

Eli Lilly

PERSON Health Care / Pharmaceuticals Momentum 5.6ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. QUIETPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$631B market cap (Indianapolis) manufactures prescription pharmaceuticals and biologics. Advanced late-stage weight-loss drug candidate and enforced 340B hospital compliance requirements in June 2026.

No active M&A or investment activity in recent signals; focus on 340B drug discount program compliance enforcement and obesity drug pipeline advancement.
-1.29
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
5.6
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
40
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Connected Entities
NYSE Morgan Stanley PlocamiumAI FDA AstraZeneca Apple Nvidia China M&A Americans Alphabet United States CEO Europe Amazon
Watch This Entity
PSI Intelligence
30-Day Trend
2026-05-12 2026-06-11 40 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.356
Spectral Shift
469.243
Sentiment-Momentum Divergence
0.000
Source Concentration
0.226
Peer Comparison
Not yet ranked. Sector-relative scoring requires at least four entities in the same BICS sector with PSI history; this entity does not yet meet the threshold or sits in a sector with insufficient peers.
Network Analysis
40 Degree Centrality
Ego Network (top connections)
NYSE (weight 23.0)Morgan Stanley (weight 18.0)PlocamiumAI (weight 16.0)FDA (weight 14.0)AstraZeneca (weight 7.0)Apple (weight 6.0)Nvidia (weight 6.0)China (weight 5.0) NYSEMorgan StanleyPlocamiumAIFDAAstraZenecaAppleNvidiaChina Eli Lilly (degree 40) Eli Lilly
Centrality History
2026-05-12 2026-06-11 40 0 Degree Mentions
EntityWeight StatusFirst Seen
NYSE 23 NEW
Morgan Stanley 18 NEW
PlocamiumAI 16 NEW
FDA 14 NEW
AstraZeneca 7 NEW
Apple 6 NEW
Nvidia 6 NEW
China 5 NEW
M&A 5 NEW
Americans 5 NEW
Alphabet 5 NEW
United States 5 NEW
CEO 4 NEW
Europe 4 NEW
Amazon 4 NEW
Microsoft 4 NEW
Walmart 4 NEW
Bloomberg 4 NEW
Beijing 3 NEW
Novartis 3 NEW
Hong Kong 3 NEW
Berkshire Hathaway 3 NEW
Broadcom 3 NEW
Elon Musk 3 NEW
SEC 3 NEW
SpaceX 3 NEW
Tesla 3 NEW
Merck 3 NEW
HHS 3 NEW
European Union 2 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-06-11 ← Intelligence Network